And that’s certainly what we’re seeing, we’re getting very positive feedback on Hytrulo. Of course, it’s taken a little while, for some of the logistics, let’s call them that, to be set up. Some of the infusion sites, getting infusions in place, is standard procedure, they needed to get new protocols in place for doing an injection instead. But we’ve certainly seen that that’s coming online now. And those injection sites are seeing the value of VYVGART well. And then the last thing that I’ll say is that not to forget that we do get self-administration in the EU, for and Japan with regards Hytrulo, or in that case, subcutaneous VYVGART. And so, we’re pleased with that as well.
Tim Van Hauwermeiren: Karl, question two.
Karl Gubitz: And yes Allison, thank you for the question. So the 7 million we’ve sold to China is to Zai Lab. This is essentially stocking the country. This is inventory now sitting in the Zai Lab warehouses. That same amount, the $7 million is both in revenues, and in cost of sales. We only of course get our share of that in royalties about $700,000. I mentioned earlier, which is in other revenues. I think from planning purposes, you have to exclude it, the revenue and the cost per sale is at zero profit – periodically, we will of course have to supply the China market, but we will always be transparent on that. But I would exclude it for planning purposes, please. Thank you.
Operator: Your next question comes from the line of Vikram Purohit from Morgan Stanley. Your line is open.
Vikram Purohit: Hi, good morning. Thanks for taking our questions. We had two regarding the potential impact of competition in MG. So first, what sort of impact have you seen at this point, if any on physician views towards VYVGART and treatment options on MG more broadly, in the past few months, given approval of the competing therapy from UCB. And how is the messaging regarding VYVGART, potentially changing in response to competition. And the second given there are additional treatments in development for MG? We’d be curious to understand your perspective on how you think the market settles out, over the coming years, and which factors you think are going to drive patient preferences, prescriber preferences, towards one treatment choice or presentation versus another, as the number of moving parts in the marketplace potentially increases in the next few years. Thanks.
Tim Van Hauwermeiren: Thanks Vikram. I will hand over these two questions to Karen. Karen?
Karen Massey: Yes, thanks for the question. Look, the way that I would think about this, and the way that we talk about it in the, the MG market is still, let’s call it quite immature. And as you said, there’s a lot of competition, a lot of – innovation coming, to the market over the coming months and years. I actually see that and we see that, as a good thing. Innovation is a great thing for patients. And certainly, the real competition that we all face is inertia, that there’s an assumption that patients are well controlled, with these therapies from decades ago. And that’s just not the case. So from my perspective, more innovation, addresses that inertia, and really expands the market over time. We’ve talked before, about it look maybe something similar to the MS market.
But what you really see, is an expansion in the treatment, the treatment rates, the diagnosis rates, and an improved outcomes for patients. Along with that. So that’s – where we would see the direction of travel for the market. And within that, I think – VYVGART is really well positioned. We have a first in class, I think we have the best molecule with the fragment technology. It comes through in the efficacy and clinical trials, but also in the real world efficacy that we’re seeing. The safety profile continues, to hold up and continues to be strong. And then obviously on the treatment burden. We started with the infusion, but with Hytrulo, we’ve been able to decouple patients from the infusion chair, and Tim spoke earlier about the continued innovation that we’re bringing, as we think about PFS, and auto injector.
So as these markets expand, I think they’ve got is incredibly well positioned, and will be continued to be intentional and disciplined and will be investing for growth.
Vikram Purohit: Thank you, Karen.
Operator: Your next question comes from the line of Manos Mastorakis from Deutsche Bank. Your line is open.
Manos Mastorakis: Hi. Thank you for taking my question. So just a quick follow-up on the CIDP and potential ITP launch in terms of sales force planning and expansion. If you can help us understand whether the new sales force will be sorry, whether new sales force will be required with different types of expertise. And what numbers are you looking to have deployed? At least in the U.S., of course. In other words, what will be the respective contribution of MG, ITP, CIDP to the overall sales force. And then secondly, for indications such as bullous pemphigoid, where potential competition could be much cheaper. For example, in dupixent, on an annual basis could be a lot cheaper than what is [indiscernible], how do you think about positioning and pricing of [indiscernible] there? Yes, that’s it? Thank you.
Tim Van Hauwermeiren: Thank you for these two questions. So Karen I suggest you take question one, and then that will address BP question, please.
Karen Massey: Yes, certainly happy to. So, I’ll start where I left off on the last question, which is that we are investing for growth, as we think about the opportunity in MG, being larger than maybe what we have thought. Obviously, the opportunity with CIDP on the incredible strength of that data, and then we’ll see where ITP, which you included, as well as PV, come out. Without getting into details, what I would say – is that we’re working up, we are working up the details at the moment. But the way to think about it is, that we’re investing that will leverage the field force, and all of the capabilities and the infrastructure that we built for MG, and that we’re thinking about investing for growth as we move forward. And we’ll be able to share more of the details of what exactly that looks like, over the coming months. But the goal for us is to maximize the opportunity and the value creation from VYVGART in the coming years.
